Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2390]

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally...

Dr Terence Friedlander - UCSF, San Francisco, USA

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )

Olaparib improves disease-free survival in high-risk early-stage HER2-negative...

Prof Andrew Tutt - Institute of Cancer Research, London, UK

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )

European Cancer Organisation: Time To Act

Professor Mark Lawler - Queens University Belfast, Belfast, UK

European Cancer Organisation: Time To Act ( Professor Mark Lawler - Queens University Belfast, Belfast, UK )

OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

UpSwinG: Real-world, non-interventional cohort study on TKI activity in...

Dr Satoru Miura - Niigata Cancer Center Hospital, Niigata, Japan

UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients with EGFRm NSCLC with uncommon mutations ( Dr Satoru Miura - Niigata Cancer Center Hospital, Niigata, Japan )

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small...

Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer ( Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France )

Efficacy and early discontinuation predictors in NSCLC patients receiving...

Dr Giulia Pasello - University of Padova, Padua, Italy

Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab ( Dr Giulia Pasello - University of Padova, Padua, Italy )

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA...

Dr Matthew Marx - Mirati Therapeutics, San Diego, USA

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours ( Dr Matthew Marx - Mirati Therapeutics, San Diego, USA )

Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients...

Prof Ravi Salgia - City of Hope, Duarte, USA

Anti-tumour activity and tolerability of RMC-4630 as a single agent in patients with RAS-addicted solid cancers ( Prof Ravi Salgia - City of Hope, Duarte, USA )

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer ( Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA )

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Decolonising palliative care

Dr Christian Ntizimira - African Center for Research on End of Life Care...

Decolonising palliative care ( Dr Christian Ntizimira - African Center for Research on End of Life Care, Kigali, Rwanda )

More from ecancer